Good idea of the year.
The FDA’s “First Generics” policy sets a priority review goal of six months for ANDAs for which there is no marketed generic equivalent.
Insider's view: this should help things. There is an 800+ product "log jam" and the only winners, to date, have been Big Pharma.
No comments:
Post a Comment